| ID | 1155 |
| Name of the vaccine | Comvax |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 6 weeks to 15 months |
| Description of the vaccine | Haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine. |
| Name of the manufacturer | Merck Sharp & Dohme Corp. |
| Name of the manufacturing country | United States |
| Year of manufacture | 1996 |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | Efficacy similar to monovalent lyophilized PedvaxHIB. |
| Vaccine formulation | Injection, suspension |
| Dosage | Three-dose regimen (2,4 and 12-15 months). |
| Mechanism of action | 0.15 to 1.0 mcg/mL |
| Route of administration | Intramuscular |
| Indications | Haemophilus influenzae type b and all known subtypes of hepatitis B virus in infants born of HBsAg negative mothers. |
| Export | Distributed by - Merck Sharp & Dohme Corp., USA |
| Approval | NA |
| Adjuvant | Aluminium hydroxy phosphate sulphate |
| Repurposing | For Hepatitis B |
| Side effects of vaccine | Injection site reactions, fever, anorexia, diarrhoea, vomiting, irritability, somnolence, crying, upper respiratory infection, rhinorrhoea, cough, rhinitis, rash, otitis media. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.drugs.com/pro/comvax-vaccine.html |
| Other name | NA |
| Additional Links | https://www.rxlist.com/comvax-drug.htm#clinpharm
|